Fundraising FoxAlwin Capital
Venture capitalBeijing · 5 people tracked
Find your way into Alwin Capital
Sign up to see every warm intro you have to Alwin Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alwin Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
The firm invests across the life sciences frontier, using scientific research and a science-lineage approach to identify opportunities in new drug development, molecular diagnostics, innovative hardware, technical services, and applied AI. It sees life sciences—built on genomics—transforming medicine through sequencing-based molecular diagnostics, synthetic-biology-driven drug platforms (small molecule to large molecule to cell/living therapies), and gene-editing-based cell and gene therapies. Bolstered by data analytics enabling digitization of biology and precision medicine, the firm applies deep scientific understanding and portfolio management expertise to build a comprehensive investment footprint and pursue outsized returns in the sector.
Source: firm website, verified Sep 20, 2026.
Team · 5 people
from the firm's website & public directoriesWhat they invest in
from 2 of 33 portfolio companiesBiotech ×2Deep Tech ×2Healthtech ×2
HQs:China×1
Investments · 33 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 12 dated
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentBioTrack CapitalIDG Capital+2 more
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.
BiotechDeep TechHealthtech
Liqun Wang(Founder)
Co-investorsPan-Lin CapitalIDG CapitalLilly Asia VenturesSherpa Healthcare Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
23魔方久事神康元码基因博雅辑因嘉晨西海大图医疗尤卡迪康景生物心岭迈德思纳福新合生物智因东方未知君泓迅生物瑞风生物百力司康科亚医疗科越生物精锋医疗罗森博特美柏生物美立刻臻和科技臻知医学艾博生物苏博医学英盛生物菲沙基因辉大基因阿诺医药齐碳科技
Frequently asked questions
- How many investments has Alwin Capital made?
- Alwin Capital has 33 tracked investments.
- What sectors does Alwin Capital focus on?
- Alwin Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices, Robotics.
- Where is Alwin Capital located?
- Alwin Capital is headquartered in Beijing, CN.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.